Niraparib and temozolomide for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of two oral medications, niraparib and temozolomide, for people whose brain tumor (glioblastoma or a related glioma) has come back after standard treatment. The goal is to see if this combination can slow or stop the tumor from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of brain tumor called glioblastoma or a similar glioma that has come back or is growing after previous treatment.
- You have already had at least one round of standard treatment (like surgery, radiation, and chemotherapy) for your tumor.
- You are able to swallow pills and manage daily activities (performance status is good).
- Your blood counts, kidney, and liver function are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
This trial tests a new combination of two drugs (flazoparib and temozolomide) given after the standard initial treatment for glioblastoma. The goal is to see if this combination is safe and effective in preventing the cancer from growing back.
This trial tests whether adding cannabinoid medicine to temozolomide helps people whose glioblastoma (GBM) has returned. It compares temozolomide plus cannabinoids versus temozolomide alone, using blinded treatment so neither you nor the team knows which option you get.
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
Hear when a new Glioma, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.